Clinical outcomes of rare hepatocellular carcinoma variants compared to pure hepatocellular carcinoma.
hepatocellular carcinoma
hepatocellular carcinoma variants
outcome
treatment
Journal
Journal of hepatocellular carcinoma
ISSN: 2253-5969
Titre abrégé: J Hepatocell Carcinoma
Pays: New Zealand
ID NLM: 101674775
Informations de publication
Date de publication:
2019
2019
Historique:
received:
10
05
2019
accepted:
26
06
2019
entrez:
16
8
2019
pubmed:
16
8
2019
medline:
16
8
2019
Statut:
epublish
Résumé
HCC variants are rare primary hepatic tumors. The aim of this study is to compare clinical characteristics and outcomes of HCC variants with pure HCC. Patients diagnosed between 2004 and 2013 with ICD-O-3 8180/3 and 8170/3-8175/3 were identified from the National Cancer Database. Univariate and multivariate survival analyses were conducted to analyze the association between histology and overall survival (OS). 80,280 patients were identified; pure HCC 78,461 (97.7%), fibrolamellar (FLHCC) 310 (0.4%), scirrhous 161 (0.2%), spindle cell 72 (0.1%), clear cell 487 (0.6%), pleomorphic 23 (0.0%), and combined HCC and cholangiocarcinoma (mixed HCC) 766 (1.0%). 76.7% were male and 72% Caucasian. Liver transplant was performed in 10.1% of pure HCC, 14.5% of mixed HCC, 16.2% of scirrhous, 6.9% of spindle cell, 8.8% of clear cell, 8.7% of pleomorphic, and 3.2% of FLHCC ( HCC variants underwent surgical resection more often than pure HCC. FLHCC had the best 5-year OS. Liver transplant was commonly performed in HCC variants.
Sections du résumé
BACKGROUND
BACKGROUND
HCC variants are rare primary hepatic tumors. The aim of this study is to compare clinical characteristics and outcomes of HCC variants with pure HCC.
METHODS
METHODS
Patients diagnosed between 2004 and 2013 with ICD-O-3 8180/3 and 8170/3-8175/3 were identified from the National Cancer Database. Univariate and multivariate survival analyses were conducted to analyze the association between histology and overall survival (OS).
RESULTS
RESULTS
80,280 patients were identified; pure HCC 78,461 (97.7%), fibrolamellar (FLHCC) 310 (0.4%), scirrhous 161 (0.2%), spindle cell 72 (0.1%), clear cell 487 (0.6%), pleomorphic 23 (0.0%), and combined HCC and cholangiocarcinoma (mixed HCC) 766 (1.0%). 76.7% were male and 72% Caucasian. Liver transplant was performed in 10.1% of pure HCC, 14.5% of mixed HCC, 16.2% of scirrhous, 6.9% of spindle cell, 8.8% of clear cell, 8.7% of pleomorphic, and 3.2% of FLHCC (
CONCLUSION
CONCLUSIONS
HCC variants underwent surgical resection more often than pure HCC. FLHCC had the best 5-year OS. Liver transplant was commonly performed in HCC variants.
Identifiants
pubmed: 31413960
doi: 10.2147/JHC.S215235
pii: 215235
pmc: PMC6660638
doi:
Types de publication
Journal Article
Langues
eng
Pagination
119-129Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Oncology. 2013;85(4):197-203
pubmed: 24051705
Lancet. 2012 Mar 31;379(9822):1245-55
pubmed: 22353262
Lancet Oncol. 2018 Jul;19(7):940-952
pubmed: 29875066
Am J Surg. 1988 May;155(5):663-6
pubmed: 2835911
J Am Coll Surg. 2012 Dec;215(6):820-30
pubmed: 22981432
Cancer. 2002 Apr 1;94(7):2040-6
pubmed: 11932907
N Engl J Med. 2018 Jul 05;379(1):54-63
pubmed: 29972759
J Surg Oncol. 2015 Dec;112(8):872-6
pubmed: 26603598
J Clin Oncol. 1999 Jan;17(1):324-31
pubmed: 10458250
J Am Coll Surg. 2014 Feb;218(2):196-205
pubmed: 24315886
Cancer. 1980 Jul 15;46(2):372-9
pubmed: 6248194
J Cancer Res Ther. 2015 Jul-Sep;11(3):656
pubmed: 26458650
United European Gastroenterol J. 2013 Oct;1(5):351-7
pubmed: 24917983
Clin Gastroenterol Hepatol. 2017 Feb;15(2):273-281.e1
pubmed: 27521507
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
World J Surg Oncol. 2016 May 23;14(1):151
pubmed: 27215576
Gastrointest Cancer Res. 2013 Jan;6(1):3-9
pubmed: 23505572
Liver Transpl. 2011 Aug;17(8):934-42
pubmed: 21438129
Hepatology. 2004 Mar;39(3):798-803
pubmed: 14999699
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Hepatogastroenterology. 2009 Jul-Aug;56(93):1086-9
pubmed: 19760947
Am J Gastroenterol. 2014 Apr;109(4):542-53
pubmed: 24513805
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Ann Surg Oncol. 2017 Feb;24(2):311-318
pubmed: 27766558
Transpl Int. 2000;13 Suppl 1:S406-9
pubmed: 11112043
Lancet. 2017 Jan 7;389(10064):56-66
pubmed: 27932229
Hepatology. 1997 Oct;26(4):877-83
pubmed: 9328308
F1000Res. 2018 Dec 19;7:1955
pubmed: 31231506
Liver Transpl. 2011 Oct;17 Suppl 2:S1-5
pubmed: 21656651
Cancer. 2006 Mar 15;106(6):1331-8
pubmed: 16475212
Surg Gynecol Obstet. 1992 Oct;175(4):299-305
pubmed: 1329242
Histopathology. 2017 Aug;71(2):217-226
pubmed: 28326574
Drug Discov Ther. 2013 Aug;7(4):137-43
pubmed: 24071575
Cancer. 1996 Jan 1;77(1):51-7
pubmed: 8630939
Dig Dis Sci. 2012 Jun;57(6):1698-707
pubmed: 22327241
AMA J Dis Child. 1956 Feb;91(2):168-86
pubmed: 13282629